These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 28319049)
1. Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. Lucca LE; Hafler DA J Clin Invest; 2017 Apr; 127(4):1218-1220. PubMed ID: 28319049 [TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283 [TBL] [Abstract][Full Text] [Related]
6. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072 [TBL] [Abstract][Full Text] [Related]
7. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614 [TBL] [Abstract][Full Text] [Related]
8. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232 [TBL] [Abstract][Full Text] [Related]
9. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
10. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Capper D; Simon M; Langhans CD; Okun JG; Tonn JC; Weller M; von Deimling A; Hartmann C; Int J Cancer; 2012 Aug; 131(3):766-8. PubMed ID: 21913188 [TBL] [Abstract][Full Text] [Related]
11. A vaccine targeting mutant IDH1 induces antitumour immunity. Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048 [TBL] [Abstract][Full Text] [Related]
12. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629 [TBL] [Abstract][Full Text] [Related]
13. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945 [TBL] [Abstract][Full Text] [Related]
14. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Bunse L; Pusch S; Bunse T; Sahm F; Sanghvi K; Friedrich M; Alansary D; Sonner JK; Green E; Deumelandt K; Kilian M; Neftel C; Uhlig S; Kessler T; von Landenberg A; Berghoff AS; Marsh K; Steadman M; Zhu D; Nicolay B; Wiestler B; Breckwoldt MO; Al-Ali R; Karcher-Bausch S; Bozza M; Oezen I; Kramer M; Meyer J; Habel A; Eisel J; Poschet G; Weller M; Preusser M; Nadji-Ohl M; Thon N; Burger MC; Harter PN; Ratliff M; Harbottle R; Benner A; Schrimpf D; Okun J; Herold-Mende C; Turcan S; Kaulfuss S; Hess-Stumpp H; Bieback K; Cahill DP; Plate KH; Hänggi D; Dorsch M; Suvà ML; Niemeyer BA; von Deimling A; Wick W; Platten M Nat Med; 2018 Aug; 24(8):1192-1203. PubMed ID: 29988124 [TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase mutations in gliomas. Waitkus MS; Diplas BH; Yan H Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014 [TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333 [TBL] [Abstract][Full Text] [Related]